Owing to a high prevalence of ER(+)PgR(−) phenotype among breast tumors recurring after tamoxifen treatment, PGR methylation status was proposed as a predictive marker for tamoxifen insensitivity [61]. The gene discussed is ESR1; the disease is breast neoplasm.